871492-83-0

Upstream product

• 54453-94-0 ethyl 6-chloro-2,4-dimethylpyridine-3-carboxylate 
• 37669-78-6 ethyl 2,4-dimethylnicotinate 
• 405058-67-5 2,4-dimethyl-1-oxy-nicotinic acid ethyl ester 
• 856937-31-0 (R)-3-[4-(4-methoxy-phenylamino)-piperidin-1-yl]-butyronitrile 
• 856931-48-1 (R)-3-(4-oxopiperidin-1-yl)butyronitrile 
• 630082-81-4 6-chloro-2,4-dimethylpyridine-3-carboxylic acid 
• 856935-52-9 (R)-[1-(3-amino-1-methyl-propyl)-piperidin-4-yl]-(4-methoxy-phenyl)-amine 

Relevant academic research and scientific papers

Design and synthesis of pyridin-2-ylmethylaminopiperidin-1-ylbutyl amide CCR5 antagonists that are potent inhibitors of M-tropic (R5) HIV-1 replication

A series of CCR5 antagonists were optimized for potent inhibition of R5 HIV-1 replication in peripheral blood mononuclear cells. Compounds that met acceptable ADME criteria, selectivity, human plasma protein binding, potency shift in the presence of α-glycoprotein were evaluated in rat and dog pharmacokinetics.

Chemokine receptor binding compounds

The present invention relates to chemokine receptor binding compounds, pharmaceutical compositions and their use. More specifically, the present invention relates to modulators of chemokine receptor activity, preferably modulators of CCR5. These compounds